Type II RAF Kinase Inhibitors [MoA] class drugs

1 result
  • ojemda - tovorafenib

    (Tovorafenib)
    Day One Biopharmaceuticals, Inc.
    Ojemda treats relapsed or refractory pediatric low-grade glioma (LGG) in patients 6 months and older with a BRAF fusion, rearrangement, or V600 mutation. Approved under accelerated approval based on response rate.